While vepdegestrant outperformed a standard treatment option in a subtype of patients, the benefit on progression-free ...

In response to President Trump’s February 13, 2025, Executive Order (EO) 14212, “Establishing The President’s Make America ...

Freenome, a biotechnology company pioneering an early cancer detection platform, today announced the publication of detailed results from the pivotal PREEMPT CRC study in JAMA.1 The publication ...

In conversation with Fierce Biotech’s Chris Hayden, Austin Read, head of PPD™ CorEvitas™ Precision Medicine, Thermo Fisher ...